Sponsor:
UCLA
Code:
NCT05553743
Conditions
Breastfeeding
COVID-19 Infection
COVID-19 Vaccine
Remdesivir
Antibiotics
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Accepted
Interventions
COVID-19 Exposure
Antibiotic
Brief summary:
Conditions
Breastfeeding
COVID-19 Infection
COVID-19 Vaccine
Remdesivir
Antibiotics
Study ID
NCT05553743
Start date
Mar 27, 2014
Status verified date
Dec, 2024
Completion date
Mar, 2040
Anticipated
Primary completion date
Mar, 2040
Anticipated
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Accepted
Enrollment
5000 participants
Anticipated
Arms
Main Study
Sub-study 100: COVID-19 Exposure
Sub-study 101: Antibiotic Exposure
Sub-study 102: P50 MPRINT Admin Supplement
Interventions
COVID-19 Exposure
Antibiotic
Primary outcome measure
Central contacts
Locations
University of California, San Diego
Recruiting
San Diego, California, United States, 92093
Sponsor
University of California, San Diego
Last update posted
Jan 31, 2025
Last verified
Dec, 2024
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Diego on 2025-01-31.